Four 20 Pharma has distribution across Germany and other European markets, serving nursing homes, pharmacies and research institutions.
Stamford-based cannabis company Curaleaf Holdings has completed its acquisition of a German producer and distributor of medical cannabis.
Curaleaf, a majority owner since 2022, said it bought out the remaining 45% stake in Four 20 Pharma.
The company says Four 20 Pharma has a distribution network across Germany and some other European markets, serving nursing homes, pharmacies and research institutions.
The full acquisition is intended to strengthen Curaleaf's vertically integrated global supply chain which also includes cultivation sources in Portugal and Canada, the company said.
Curaleaf has launched the Four 20 brand in the United Kingdom and Poland and intends to continue expanding distribution across additional international markets.
“This investment has been a meaningful, strategic anchor in our international strategy, and we're looking forward to continued long-term growth in Europe,” said Curaleaf CEO Boris Jordan.
